Value of BRAF V600E in High-Risk Thyroid Nodules with Benign Cytology Results

References

1. 1.↵
   2. Sipos JA

   . Advances in ultrasound for the diagnosis and management of thyroid cancer. Thyroid 2009;19:1363–72 doi:10.1089/thy.2009.1608 pmid:20001718

   CrossRefPubMed
2. 2.↵
   2. Gharib H,
   3. Papini E,
   4. Garber JR, et al

   ; AACE/ACE/AME Task Force on Thyroid Nodules. American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules: 2016 Update. Endocr Pract 2016;22:622–39 doi:10.4158/EP161208.GL pmid:27167915

   CrossRefPubMed
3. 3.↵
   2. Haugen BR,
   3. Alexander EK,
   4. Bible KC, et al

   . 2015 American Thyroid Association Management. Thyroid 2016;26:1–133 doi:10.1089/thy.2015.0020 pmid:26462967

   CrossRefPubMed
4. 4.↵
   2. Yoon JH,
   3. Moon HJ,
   4. Kim E-K, et al

   . Inadequate cytology in thyroid nodules: should we repeat aspiration or follow-up? Ann Surg Oncol 2011;18:1282–89 doi:10.1245/s10434-011-1605-7 pmid:21331807

   CrossRefPubMed
5. 5.↵
   2. Yoon JH,
   3. Kim EK,
   4. Moon HJ, et al

   . Is follow-up BRAF(V600E) mutation analysis helpful in the differential diagnosis of thyroid nodules with negative results on initial analysis? PLoS One 2013;8:e58592 doi:10.1371/journal.pone.0058592 pmid:23505540

   CrossRefPubMed
6. 6.↵
   2. Moon HJ,
   3. Son E,
   4. Kim EK, et al

   . The diagnostic values of ultrasound and ultrasound-guided fine needle aspiration in subcentimeter-sized thyroid nodules. Ann Surg Oncol 2012;19:52–59 doi:10.1245/s10434-011-1813-1 pmid:21638096

   CrossRefPubMed
7. 7.↵
   2. Kim SK,
   3. Hwang TS,
   4. Yoo YB, et al

   . Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mutation status. J Clin Endocrinol Metab 2011;96:658–64 doi:10.1210/jc.2010-1082 pmid:21239517

   CrossRefPubMedWeb of Science
8. 8.↵
   2. Moon HJ,
   3. Kim E-K,
   4. Chung WY, et al

   . Diagnostic value of BRAF(V600E) mutation analysis of thyroid nodules according to ultrasonographic features and the time of aspiration. Ann Surg Oncol 2011;18:792–99 doi:10.1245/s10434-010-1354-z pmid:20945104

   CrossRefPubMed
9. 9.↵
   2. Koh J,
   3. Choi JR,
   4. Han KH, et al

   . Proper indication of BRAF(V600E) mutation testing in fine-needle aspirates of thyroid nodules. PLoS One 2013;8:e64505 doi:10.1371/journal.pone.0064505 pmid:23717622

   CrossRefPubMed
10. 10.↵
    2. Zhang Y,
    3. Xu T,
    4. Cui D, et al

    . Value of TIRADS, BSRTC and FNA-BRAF V600E mutation analysis in differentiating high-risk thyroid nodules. Sci Rep 2015;5:16927 doi:10.1038/srep16927 pmid:26597052

    CrossRefPubMed
11. 11.↵
    2. Lew JI,
    3. Snyder RA,
    4. Sanchez YM, et al

    . Fine needle aspiration of the thyroid: correlation with final histopathology in a surgical series of 797 patients. J Am Coll Surg 2011;213:188–94; discussion 194–95 doi:10.1016/j.jamcollsurg.2011.04.029 pmid:21601489

    CrossRefPubMed
12. 12.↵
    2. Yeh MW,
    3. Demircan O,
    4. Ituarte P, et al

    . False-negative fine-needle aspiration cytology results delay treatment and adversely affect outcome in patients with thyroid carcinoma. Thyroid 2004;14:207–15 doi:10.1089/105072504773297885 pmid:15072703

    CrossRefPubMedWeb of Science
13. 13.↵
    2. Shrestha M,
    3. Crothers BA,
    4. Burch HB

    . The impact of thyroid nodule size on the risk of malignancy and accuracy of fine-needle aspiration: a 10-year study from a single institution. Thyroid 2012;22:1251–56 doi:10.1089/thy.2012.0265 pmid:22962940

    CrossRefPubMed
14. 14.↵
    2. Cavallo A,
    3. Johnson DN,
    4. White MG, et al

    . Thyroid nodule size at ultrasound as a predictor of malignancy and final pathologic size. Thyroid 2017;27:641–50 doi:10.1089/thy.2016.0336 pmid:28052718

    CrossRefPubMed
15. 15.↵
    2. McCoy KL,
    3. Jabbour N,
    4. Ogilvie JB, et al

    . The incidence of cancer and rate of false-negative cytology in thyroid nodules greater than or equal to 4 cm in size. Surgery 2007;142:837–44; discussion 844.e1–3 doi:10.1016/j.surg.2007.08.012 pmid:18063065

    CrossRefPubMedWeb of Science
16. 16.↵
    2. Agcaoglu O,
    3. Aksakal N,
    4. Ozcinar B, et al

    . Factors that affect the false-negative outcomes of fine-needle aspiration biopsy in thyroid nodules. Int J Endocrinol 2013;2013:126084doi:10.1155/2013/12608444 pmid:23935616

    CrossRefPubMed
17. 17.↵
    2. Lu ZZ,
    3. Zhang Y,
    4. Wei SF, et al

    . Outcome of papillary thyroid microcarcinoma: study of 1,990 cases. Mol Clin Oncol 2015;3:672–76 doi:10.3892/mco.2015.495 pmid:26137285

    CrossRefPubMed
18. 18.↵
    2. Cohen Y,
    3. Rosenbaum E,
    4. Clark DP, et al

    . Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clin Cancer Res 2004;10:2761–65 doi:10.1158/1078-0432.CCR-03-0273 pmid:15102681

    Abstract/FREE Full Text
19. 19.↵
    2. Kim SW,
    3. Lee JI,
    4. Kim JW, et al

    . BRAFV600E mutation analysis in fine-needle aspiration cytology specimens for evaluation of thyroid nodule: a large series in a BRAFV600E-prevalent population. J Clin Endocrinol Metab 2010;95:3693–700 doi:10.1210/jc.2009-2795 pmid:20501689

    CrossRefPubMedWeb of Science
20. 20.↵
    2. Xing M,
    3. Tufano RP,
    4. Tufaro AP, et al

    . Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab 2004;89:2867–72 doi:10.1210/jc.2003-032050 pmid:15181070

    CrossRefPubMedWeb of Science
21. 21.↵
    2. Proietti A,
    3. Borrelli N,
    4. Giannini R, et al

    . Molecular characterization of 54 cases of false-negative fine-needle aspiration among 1347 papillary thyroid carcinomas. Cancer Cytopathol 2014;122:751–59 doi:10.1002/cncy.21454 pmid:24913568

    CrossRefPubMed
22. 22.↵
    2. Kim SY,
    3. Kim EK,
    4. Kwak JY, et al

    . What to do with thyroid nodules showing benign cytology and BRAF(V600E) mutation? A study based on clinical and radiologic features using a highly sensitive analytic method. Surgery 2015;157:354–61 doi:10.1016/j.surg.2014.09.003 pmid:25616949

    CrossRefPubMed
23. 23.↵
    2. Kim WY,
    3. Kim H,
    4. Hwang TS

    . Comparison between real-time PCR and pyrosequencing for detection of BRAF V600E mutation in thyroid fine-needle aspirates. Appl Immunohistochem Mol Morphol 2017;25:358–65 doi:10.1097/PAI.0000000000000308 pmid:26657877

    CrossRefPubMed
24. 24.↵
    2. Ellison G,
    3. Donald E,
    4. McWalter G, et al

    . A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples. J Exp Clin Cancer Res 2010;29:132 doi:10.1186/1756-9966-29-132 pmid:20925915

    CrossRefPubMed
25. 25.↵
    2. Huang T,
    3. Zhuge J,
    4. Zhang WW

    . Sensitive detection of BRAF V600E mutation by Amplification Refractory Mutation System (ARMS)-PCR. Biomarker Res 2013;1:3 doi:10.1186/2050-7771-1-3 pmid:24252159

    CrossRefPubMed
26. 26.↵
    2. DiLorenzo M,
    3. Miller J,
    4. Tuluc M, et al

    . False-positive FNA due to highly sensitive BRAF assay. Endocr Pract 2014;20:e8–10 doi:10.4158/EP13294.CR pmid:24014015

    CrossRefPubMed